EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study

Silvester Lowe, Vishal Satikuvar, Tanjia M Syeda, Monica Cal, Pascal Mäser, Marcel Kaiser, Hachemi Kadri iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.202501072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Silvester Lowe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, UK. Hauptthemen laut MEDLINE: Prodrugs, ProTides, Antiprotozoal Agents, Kinetoplastida. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Challenges Research Fund, Royal Society of Chemistry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low‐ and middle‐income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates. However, their clinical utility is limited by poor cellular uptake and rapid metabolism. Herein, we report the application of the ProTide prodrug technology, a clinically validated approach that enhances the intracellular delivery of nucleoside monophosphates for the treatment of kinetoplastids infections. As a proof of concept, a focused library of zidovudine (AZT) and cordycepin ProTide prodrugs was designed, synthesized, and evaluated for antiparasitic activity against T. b. rhodesiense , T. cruzi , and L. donovani , as well as for cytotoxicity in L6 rat myoblasts. Out of these, compound 16 exhibited substantial serum stability and potent activity (IC 50 = 5 nM; selectivity index, SI = 2,560) against T. b. rhodesiense with robust activity also observed against T. cruzi and L. donovani. These findings establish the ProTide prodrug technology as a promising strategy for optimizing nucleoside analogues against kinetoplastid parasites and provide a framework for the development of new therapeutics for NTDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsProTidesAntiprotozoal AgentsKinetoplastidaAnimalsRatsParasitic Sensitivity TestsTrypanosoma cruziStructure-Activity RelationshipMolecular StructureProof of Concept StudyTrypanosoma brucei rhodesienseLeishmania donovaniDose-Response Relationship, Drug

Stichwörter der Autor:innen

cordycepinkinetoplastidsneglected tropical diseasesnucleoside analoguesproTide

Substanzen

ProdrugsProTidesAntiprotozoal Agents

Autor:innen und Institutionen

  • Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, UK.
  • Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute (Swiss TPH), University of Basel, Basel, Switzerland.

ORCID-Profile: Hachemi Kadri

Förderung

  • Global Challenges Research Fund
  • Royal Society of Chemistry

Zitieren

APA

Lowe, S., Satikuvar, V., Syeda, T. M., Cal, M., Mäser, P., Kaiser, M., & Kadri, H. (2026). Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study. ChemMedChem. https://doi.org/10.1002/cmdc.202501072

Vancouver

Lowe S, Satikuvar V, Syeda TM, Cal M, Mäser P, Kaiser M, et al. Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study. ChemMedChem. 2026. doi:10.1002/cmdc.202501072

BibTeX
@article{Lowe2026,
  author = {Lowe, Silvester and Satikuvar, Vishal and Syeda, Tanjia M and Cal, Monica and Mäser, Pascal and Kaiser, Marcel and Kadri, Hachemi},
  title = {Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202501072}
}
Kostenlos starten →